2.68
price up icon3.33%   0.08
 
loading
Immunitybio Inc stock is traded at $2.68, with a volume of 7.92M. It is up +3.33% in the last 24 hours and up +7.04% over the past month. ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.60
Open:
$2.61
24h Volume:
7.92M
Relative Volume:
1.04
Market Cap:
$2.37B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.7629
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+6.19%
1M Performance:
+7.04%
6M Performance:
-46.69%
1Y Performance:
-59.36%
1-Day Range:
Value
$2.505
$2.71
1-Week Range:
Value
$2.43
$2.79
52-Week Range:
Value
$1.83
$7.63

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
671
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IBRX
Immunitybio Inc
2.685 2.37B 1.31M -597.65M -425.62M -0.97
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.45 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.39 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 40.37M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.42 6.19B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
491.45 64.44B 14.09B 4.50B 2.96B 39.28

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy

Immunitybio Inc Stock (IBRX) Latest News

pulisher
09:46 AM

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com

09:46 AM
pulisher
09:44 AM

Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail

09:44 AM
pulisher
06:40 AM

Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN

06:40 AM
pulisher
May 29, 2025

ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView

May 29, 2025
pulisher
May 29, 2025

ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView

May 29, 2025
pulisher
May 28, 2025

ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus

May 28, 2025
pulisher
May 27, 2025

Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace

May 27, 2025
pulisher
May 27, 2025

ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus

May 27, 2025
pulisher
May 27, 2025

ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle East | IBRX Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News

May 23, 2025
pulisher
May 22, 2025

Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey

May 22, 2025
pulisher
May 22, 2025

Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World

May 22, 2025
pulisher
May 20, 2025

Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever” - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Piper Sandler Upgrades ImmunityBio (IBRX) - Nasdaq

May 20, 2025
pulisher
May 20, 2025

10 Firms Drenched in Red Today - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Jim Cramer’s Recent Thoughts on These 15 Stocks - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

Piper Sandler raises ImmunityBio stock rating, target to $5 By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Upgraded to Overweight by Piper Sandler - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Why ImmunityBio, Inc. (IBRX) Surged Last Week - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Analyst Upgrade and Price Target Increase | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Piper Sandler raises ImmunityBio stock rating, target to $5 - Investing.com

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Ca - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Cancer Therapies | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Why ImmunityBio’s Stock is on the Rise - TipRanks

May 20, 2025
pulisher
May 20, 2025

ImmunityBio (IBRX) Receives Upgrade from Piper Sandler | IBRX Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 19, 2025
pulisher
May 19, 2025

FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal

May 19, 2025
pulisher
May 18, 2025

Mercer Global Advisors Inc. ADV Purchases 8,359 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 18, 2025
pulisher
May 18, 2025

ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025
pulisher
May 16, 2025

Biotechs need a new guidebook to parse FDA messaging: a Perspective - BioCentury

May 16, 2025
pulisher
May 16, 2025

Q2 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World

May 16, 2025
pulisher
May 15, 2025

ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo

May 14, 2025
pulisher
May 14, 2025

HC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX) - Defense World

May 14, 2025
pulisher
May 14, 2025

Raymond James Financial Inc. Takes $172,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 14, 2025
pulisher
May 13, 2025

BTIG maintains ImmunityBio stock Buy rating, $6 target By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

BTIG maintains ImmunityBio stock Buy rating, $6 target - Investing.com

May 13, 2025
pulisher
May 13, 2025

Why ImmunityBio Stock is Gaining Momentum - TipRanks

May 13, 2025
pulisher
May 13, 2025

Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Hsbc Holdings PLC Takes $44,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World

May 13, 2025
pulisher
May 13, 2025

ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum - TipRanks

May 13, 2025
pulisher
May 12, 2025

Why ImmunityBio, Inc. (IBRX) Soared Today - MSN

May 12, 2025
pulisher
May 12, 2025

ImmunityBio: Q1 Earnings Snapshot - MySA

May 12, 2025

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
SOON-SHIONG PATRICK
See remarks
Feb 22 '25
Option Exercise
0.00
114,329
0
29,588,261
Sachs David C.
Chief Financial Officer
Feb 22 '25
Option Exercise
0.00
40,650
0
241,480
Adcock Richard
CEO & President
Feb 22 '25
Option Exercise
0.00
152,439
0
412,585
Simon Barry J.
Director
Feb 22 '25
Option Exercise
0.00
15,243
0
3,249,024
Simon Barry J.
Director
Jan 22 '25
Option Exercise
2.00
110,020
219,864
3,233,781
Adcock Richard
CEO & President
Dec 31 '24
Option Exercise
0.00
34,483
0
277,621
Sachs David C.
Chief Financial Officer
Dec 31 '24
Option Exercise
0.00
30,397
0
216,235
LAUER REGAN J
Chief Accounting Officer
Dec 15 '24
Option Exercise
0.00
21,031
0
115,365
$1.075
price up icon 2.38%
$30.37
price up icon 0.98%
$570.04
price down icon 1.10%
$292.90
price up icon 2.57%
$4.64
price up icon 3.45%
$502.32
price down icon 17.32%
Cap:     |  Volume (24h):